查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570828

血管收缩素转化酵素抑制剂市场：按药物类型、疾病类型、剂型、通路、病患属性分类 - 2025-2030 年全球预测

Angiotensin Converting Enzyme Inhibitors Market by Drug Type, Disease Type, Dosage Form, Distribution Channel, Patient Demographics - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血管收缩素转化酵素抑制剂市值为37亿美元，预计到2024年将达到39.2亿美元，复合年增长率为6.23%，到2030年将达到56.5亿美元。

血管收缩素转化酵素（ACE）抑制剂是一类主要用于治疗高血压和郁血性的药物。 ACE抑制剂抑制血管收缩素I向血管收缩素II的转化，导致血管舒张和血压下降。全球高血压和心血管疾病的流行推动了对 ACE 抑制剂的需求，因此这些药物对于管理心血管健康至关重要。 ACE抑制剂的用途不仅限于高血压，还延伸到糖尿病肾臟病和心肌梗塞后的治疗，使其在治疗方法中变得越来越重要。主要最终用户包括医院、诊所和私人患者，推动了不同医疗保健环境中的持续需求。推动市场成长的主要因素包括与生活方式相关的健康状况发病率上升、心血管健康意识增强等。此外，全球人口老化导致慢性心血管疾病盛行率上升，也推动了市场需求。然而，市场面临一些限制，例如专利到期到期导致学名药竞争，以及咳嗽和血管性水肿等可能限制患者依从性的副作用。监管障碍和严格临床试验的需要为市场扩张带来了进一步的挑战。儘管如此，仍有开发创新製剂技术的机会，以改善药物传递和患者依从性，包括释放曲线和与其他高血压药物的联合治疗。监控医疗基础设施正在改善的新兴市场也提供了潜在的成长潜力。为了利用这些机会，公司需要注重策略伙伴关係关係以扩大分销，投资于更新、更有效的配方的研发，并探索用于远端患者监护和依从性追踪的数位健康技术。该市场本质上是竞争性的，需要不断创新并适应法规环境和患者需求，以在全球市场格局中保持相关性和竞争力。

主要市场统计
基准年[2023] 37亿美元
预测年份 [2024] 39.2亿美元
预测年份 [2030] 56.5亿美元
复合年增长率（%） 6.23%

市场动态：快速发展的血管收缩素转化酵素抑制剂市场的关键市场洞察

供需的动态交互作用正在改变血管收缩素转化酵素抑制剂市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球心血管疾病和高血压盛行率不断上升，增加了对有效治疗方案的需求。
    • 人口老化加剧导致需要血管收缩素转化酵素抑制剂的慢性疾病盛行率增加
    • 药物研发进展提高血管收缩素转化酵素抑制剂的有效性
    • 支持在治疗通讯协定中使用血管收缩素转化酵素抑制剂的政府措施和医疗保健政策
  • 市场限制因素
    • 对血管收缩素转化酵素抑制剂的需求可能会减少。
    • 与长期使用血管收缩素转化酵素抑制剂相关的副作用可能会降低患者的依从性
  • 市场机会
    • 先进的配方技术可提高 Ace 抑制剂的生物有效性和标靶递送
    • 基于基因谱分析客製化 Ace 抑制剂治疗的个人化医疗机会
    • 扩大 Ace 抑制剂在肾臟疾病和糖尿病等合併症治疗的应用
  • 市场挑战
    • 来自替代疗法和学名药的竞争挑战了血管收缩素转化酵素抑制剂的市场主导地位
    • 病人依从性和教育问题影响血管收缩素转化酵素抑制剂的疗效和市场渗透率

波特五力：驾驭血管收缩素转化酵素抑制剂市场的策略工具

波特的五力框架是了解血管收缩素转化酵素抑制剂市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血管收缩素转化酵素抑制剂市场的外部影响

外部宏观环境因素在塑造血管收缩素转化酵素抑制剂市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解血管收缩素转化酵素抑制剂市场的竞争状况

血管收缩素转化酵素抑制剂市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵血管收缩素转化酵素抑制剂市场供应商的绩效评估

FPNV 定位矩阵是评估血管收缩素转化酵素抑制剂市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製血管收缩素转化酵素抑制剂市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对血管收缩素转化酵素抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球心血管疾病和高血压的盛行率正在上升，增加了对有效治疗方法的需求。
      • 人口老化正在增加需要治疗的慢性病的发生率。
      • 药物研发进展提高血管收缩素转化酵素抑制剂的有效性
      • 支持在治疗通讯协定中使用血管收缩素转化酵素抑制剂的政府措施和医疗保健政策
    • 抑制因素
      • 增加高血压替代疗法的可用性和选择可能会减少对血管收缩素转化酵素抑制剂的需求。
      • 与长期使用血管收缩素转化酵素抑制剂相关的副作用可能会降低患者的依从性
    • 机会
      • 先进的配方技术可提高 ACE 抑制剂的生物利用度和标靶递送
      • 基于基因谱分析的客製化 ACE 抑制剂治疗的个人化医疗机会
      • 扩大血管张力素转换酶抑制剂在肾臟病和糖尿病等併发症治疗的应用
    • 任务
      • 血管收缩素转化酵素抑制剂的市场主导地位受到替代疗法和学名药竞争的挑战
      • 患者依从性和教育问题会影响血管收缩素转化酵素抑制剂的疗效和市场渗透率。
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章血管收缩素转化酵素抑制剂市场：依药物类型

  • 特异性ACE抑制剂
  • 某些 ACE 抑制剂

第七章血管收缩素转化酵素抑制剂市场：依疾病类型

  • 心臟病
    • 慢性心臟衰竭
    • 冠状动脉疾病
  • 高血压
    • 原发性高血压
    • 次发性高血压
  • 肾臟疾病
    • 慢性肾臟病
    • 糖尿病肾臟病

第八章血管收缩素转化酵素抑制剂市场：按剂型

  • 胶囊
  • 可注射的
  • 药片

第九章血管收缩素转化酵素抑制剂市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第10章血管收缩素转化酵素抑制剂市场：依患者特征

  • 成人
  • 老年人
  • 儿科的

第十一章 美洲血管收缩素转化酵素抑制剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区血管收缩素转化酵素抑制剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲血管收缩素转化酵素抑制剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C05FB

The Angiotensin Converting Enzyme Inhibitors Market was valued at USD 3.70 billion in 2023, expected to reach USD 3.92 billion in 2024, and is projected to grow at a CAGR of 6.23%, to USD 5.65 billion by 2030.

Angiotensin Converting Enzyme (ACE) Inhibitors are a class of medications primarily used to treat hypertension and congestive heart failure. They work by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced blood pressure. The necessity of ACE inhibitors stems from the global prevalence of hypertension and cardiovascular diseases, positioning these drugs as crucial in managing cardiovascular health. Their application extends beyond hypertension to include diabetic nephropathy and post-myocardial infarction treatment, enhancing their significance in therapeutic regimens. The primary end-users include hospitals, clinics, and individual patients, prompting consistent demand across diverse healthcare settings. Key factors driving market growth include the rising incidence of lifestyle-related health conditions and increasing awareness about cardiovascular health. Additionally, the aging global population underpinning a higher prevalence of chronic cardiovascular conditions propels market demand. However, the market faces limitations such as patent expirations leading to generic drug competition, and side effects like cough and angioedema, which may limit patient compliance. Regulatory hurdles and the need for rigorous clinical trials further challenge market expansion. Nonetheless, opportunities exist in developing innovative formulation techniques to improve drug delivery and patient adherence, such as release profiles and combination therapies with other antihypertensives. Monitoring emerging markets where healthcare infrastructure is improving also offers potential growth avenues. To capitalize on these opportunities, companies should focus on strategic partnerships for expanded distribution, invest in research and development for newer, more efficient drug formulations, and explore digital health technologies for remote patient monitoring and adherence tracking. The market is inherently competitive, necessitating constant innovation and adaptation to regulatory environments and patient needs, thus maintaining relevance and competitive advantage in the global market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 3.70 billion
Estimated Year [2024] USD 3.92 billion
Forecast Year [2030] USD 5.65 billion
CAGR (%) 6.23%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Angiotensin Converting Enzyme Inhibitors Market

The Angiotensin Converting Enzyme Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
    • Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
    • Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
    • Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
  • Market Restraints
    • Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
    • Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
  • Market Opportunities
    • Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
    • Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
    • Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
  • Market Challenges
    • Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
    • Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors

Porter's Five Forces: A Strategic Tool for Navigating the Angiotensin Converting Enzyme Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Angiotensin Converting Enzyme Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Angiotensin Converting Enzyme Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Angiotensin Converting Enzyme Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Angiotensin Converting Enzyme Inhibitors Market

A detailed market share analysis in the Angiotensin Converting Enzyme Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Angiotensin Converting Enzyme Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Angiotensin Converting Enzyme Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Angiotensin Converting Enzyme Inhibitors Market

A strategic analysis of the Angiotensin Converting Enzyme Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Angiotensin Converting Enzyme Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Angiotensin Converting Enzyme Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Non-Specific ACE Inhibitors and Specific ACE Inhibitors.
  • Based on Disease Type, market is studied across Heart Diseases, Hypertension, and Kidney Diseases. The Heart Diseases is further studied across Chronic Heart Failure and Coronary Artery Disease. The Hypertension is further studied across Primary Hypertension and Secondary Hypertension. The Kidney Diseases is further studied across Chronic Kidney Diseases and Diabetic Nephropathy.
  • Based on Dosage Form, market is studied across Capsules, Injectable, and Tablets.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Patient Demographics, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cardiovascular diseases and hypertension globally driving demand for effective treatment options
      • 5.1.1.2. Growing aging population contributing to increased incidence of chronic conditions requiring angiotensin converting enzyme inhibitors
      • 5.1.1.3. Advancements in pharmaceutical research and development enhancing efficacy of angiotensin converting enzyme inhibitors
      • 5.1.1.4. Government initiatives and healthcare policies supporting the use of angiotensin converting enzyme inhibitors in treatment protocols
    • 5.1.2. Restraints
      • 5.1.2.1. Increasing availability and preference for alternative treatments for hypertension may reduce demand for angiotensin converting enzyme inhibitors
      • 5.1.2.2. Adverse side effects associated with prolonged use of angiotensin converting enzyme inhibitors may reduce patient adherence
    • 5.1.3. Opportunities
      • 5.1.3.1. Advanced formulation techniques for improved bioavailability and targeted delivery of ace inhibitors
      • 5.1.3.2. Opportunities in personalized medicine with customized ace inhibitor treatments based on genetic profiling
      • 5.1.3.3. Growing application of ace inhibitors in managing comorbid conditions such as kidney disease and diabetes
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from alternative therapies and generic drugs challenges the market dominance of angiotensin converting enzyme inhibitors
      • 5.1.4.2. Patient adherence and education issues impact the effectiveness and market uptake of angiotensin converting enzyme inhibitors
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Angiotensin Converting Enzyme Inhibitors Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Non-Specific ACE Inhibitors
  • 6.3. Specific ACE Inhibitors

7. Angiotensin Converting Enzyme Inhibitors Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Heart Diseases
    • 7.2.1. Chronic Heart Failure
    • 7.2.2. Coronary Artery Disease
  • 7.3. Hypertension
    • 7.3.1. Primary Hypertension
    • 7.3.2. Secondary Hypertension
  • 7.4. Kidney Diseases
    • 7.4.1. Chronic Kidney Diseases
    • 7.4.2. Diabetic Nephropathy

8. Angiotensin Converting Enzyme Inhibitors Market, by Dosage Form

  • 8.1. Introduction
  • 8.2. Capsules
  • 8.3. Injectable
  • 8.4. Tablets

9. Angiotensin Converting Enzyme Inhibitors Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Angiotensin Converting Enzyme Inhibitors Market, by Patient Demographics

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Angiotensin Converting Enzyme Inhibitors Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan plc
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Boehringer Ingelheim GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Daiichi Sankyo Company, Limited
  • 9. Eli Lilly and Company
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Johnson & Johnson
  • 13. Merck & Co., Inc.
  • 14. Mylan N.V.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Roche Holding AG
  • 18. Sanofi S.A.
  • 19. Takeda Pharmaceutical Company Limited
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY NON-SPECIFIC ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY SPECIFIC ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CHRONIC HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PRIMARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY SECONDARY HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CHRONIC KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 182. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 199. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 207. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 215. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 223. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 231. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 239. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 247. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 255. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 263. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 271. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HEART DISEASES, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY HYPERTENSION, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY KIDNEY DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 279. POLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. POLAND ANGIOTENSIN CONVERTING ENZYME INHIBITORS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)

TABLE 28